JO3410B1 - تركيبة أريبيبرازول مجفف بالتبريد - Google Patents

تركيبة أريبيبرازول مجفف بالتبريد

Info

Publication number
JO3410B1
JO3410B1 JOP/2012/0141A JOP20120141A JO3410B1 JO 3410 B1 JO3410 B1 JO 3410B1 JO P20120141 A JOP20120141 A JO P20120141A JO 3410 B1 JO3410 B1 JO 3410B1
Authority
JO
Jordan
Prior art keywords
freeze
aripiprazole
dried
dried aripiprazole
aripiprazole formulation
Prior art date
Application number
JOP/2012/0141A
Other languages
English (en)
Inventor
Hiraoka Shogo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46420491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3410(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3410B1 publication Critical patent/JO3410B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

يتعلق الاختارع الحالي في أحد أهدافه بتوفير صيغة مسحوق أريبيبرازول مجففة بالتجميد تظهر قابلية جيدة للتشتت ويتم تشتيتها بسهولة في معلق متجانس عند إعادة تكوينها باستخدام الماء. يوفر الاختراع الحالي صيغة أريبيبرازول مجففة بالتجميد تم الحصول عليها بواسطة عملية تشتمل على الخطوات الخاصة بالرش لتجميد معلق من أريبيبرازول مشتمل على (1) أريبيبرازول، (2) مادة ناقلة للأريبيبرازول، و (3) ماء للحقن، ومن ثم التجفيف.
JOP/2012/0141A 2011-06-07 2012-06-03 تركيبة أريبيبرازول مجفف بالتبريد JO3410B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161494088P 2011-06-07 2011-06-07

Publications (1)

Publication Number Publication Date
JO3410B1 true JO3410B1 (ar) 2019-10-20

Family

ID=46420491

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0141A JO3410B1 (ar) 2011-06-07 2012-06-03 تركيبة أريبيبرازول مجفف بالتبريد

Country Status (30)

Country Link
US (3) US11154507B2 (ar)
EP (1) EP2717859B1 (ar)
JP (1) JP6012637B2 (ar)
KR (1) KR102014124B1 (ar)
CN (3) CN106389357A (ar)
AR (2) AR086682A1 (ar)
AU (1) AU2012267810B2 (ar)
BR (1) BR112013031459B1 (ar)
CA (1) CA2837693C (ar)
CO (1) CO6842019A2 (ar)
CY (1) CY1118561T1 (ar)
DK (1) DK2717859T3 (ar)
EA (1) EA023951B1 (ar)
ES (1) ES2599479T3 (ar)
HK (1) HK1191245A1 (ar)
HR (1) HRP20161357T1 (ar)
HU (1) HUE031723T2 (ar)
IL (1) IL229467A (ar)
JO (1) JO3410B1 (ar)
LT (1) LT2717859T (ar)
MX (1) MX354473B (ar)
MY (1) MY166052A (ar)
PL (1) PL2717859T3 (ar)
PT (1) PT2717859T (ar)
SG (1) SG195046A1 (ar)
SI (1) SI2717859T1 (ar)
TW (1) TWI519320B (ar)
UA (1) UA112186C2 (ar)
WO (1) WO2012169662A1 (ar)
ZA (1) ZA201308868B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
CN105663057A (zh) * 2015-12-30 2016-06-15 中国药科大学 阿立哌唑长效混悬剂及其制备方法
US20190160002A1 (en) 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
CN115768407A (zh) * 2020-05-21 2023-03-07 江苏先声药业有限公司 一种含依匹哌唑药物组合物及其制备方法
CN112656767A (zh) * 2021-01-22 2021-04-16 烟台东诚药业集团股份有限公司 一种依诺肝素钠注射制剂及其制备方法
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
WO2023083212A1 (zh) * 2021-11-10 2023-05-19 广东东阳光药业有限公司 一种喹啉类药物的组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB9105705D0 (en) 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050019607A1 (en) 2003-06-30 2005-01-27 Franky So OLED device with mixed emissive layer
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
EP1732107A4 (en) 2004-03-30 2009-05-13 Fujitsu Microelectronics Ltd METHOD FOR CORRECTING EXPOSURE DATA TO AN ELECTRON BEAM
US7731873B2 (en) 2005-08-09 2010-06-08 Coopervision International Holding Company, Lp Contact lens mold assemblies and systems and methods of producing same
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
HUE036214T2 (hu) * 2007-07-31 2018-06-28 Otsuka Pharma Co Ltd Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására

Also Published As

Publication number Publication date
BR112013031459A2 (pt) 2016-12-06
PT2717859T (pt) 2016-10-11
CO6842019A2 (es) 2014-01-20
IL229467A0 (en) 2014-01-30
HK1191245A1 (zh) 2014-07-25
ZA201308868B (en) 2015-02-25
AU2012267810B2 (en) 2016-08-11
CA2837693A1 (en) 2012-12-13
CN106389357A (zh) 2017-02-15
CN103596557A (zh) 2014-02-19
JP2014516025A (ja) 2014-07-07
TW201302246A (zh) 2013-01-16
AR086682A1 (es) 2014-01-15
SG195046A1 (en) 2013-12-30
WO2012169662A1 (en) 2012-12-13
CN108379231A (zh) 2018-08-10
KR20140041673A (ko) 2014-04-04
EP2717859B1 (en) 2016-08-31
BR112013031459B1 (pt) 2022-02-22
CY1118561T1 (el) 2017-07-12
ES2599479T3 (es) 2017-02-01
KR102014124B1 (ko) 2019-08-26
SI2717859T1 (sl) 2017-01-31
JP6012637B2 (ja) 2016-10-25
HUE031723T2 (hu) 2017-07-28
NZ618111A (en) 2015-04-24
HRP20161357T1 (hr) 2016-12-02
EP2717859A1 (en) 2014-04-16
EA023951B1 (ru) 2016-07-29
EA201391818A1 (ru) 2014-04-30
PL2717859T3 (pl) 2017-01-31
MY166052A (en) 2018-05-22
US11154507B2 (en) 2021-10-26
AR124163A2 (es) 2023-02-22
CA2837693C (en) 2015-11-03
DK2717859T3 (en) 2016-11-21
US20240041774A1 (en) 2024-02-08
IL229467A (en) 2017-08-31
AU2012267810A1 (en) 2013-12-12
LT2717859T (lt) 2016-11-25
US20220008341A1 (en) 2022-01-13
MX354473B (es) 2018-03-07
MX2013014186A (es) 2014-03-21
US20140112993A1 (en) 2014-04-24
TWI519320B (zh) 2016-02-01
UA112186C2 (uk) 2016-08-10

Similar Documents

Publication Publication Date Title
JO3410B1 (ar) تركيبة أريبيبرازول مجفف بالتبريد
MX2021003256A (es) Articulo abrasivo que incluye particulas abrasivas perfiladas.
WO2014047486A3 (en) Spray drying microcapsules
MX2016003711A (es) Particulas.
PH12015500900A1 (en) A stabilized pemetrexed formulation
MX2015001958A (es) Composiciones mejoradas de particulas substancialmente esfericas.
MX2020002544A (es) Sales de glicopirrolato.
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
HUE038664T2 (hu) Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása
WO2013119468A3 (en) Improvement of stability of phytase with phytic acid, and compositions|comprising phytase and phytic acid
CA2905610C (en) Hyaluronic acid derivatives
EP3043811A4 (en) Compositions and methods for the delivery of molecules into live cells
WO2014199322A3 (en) Wear resistant compositions with low particulate contamination and method of making those compositions
NZ628433A (en) Chitosan-derived compositions
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MX2014014868A (es) Proceso para producir medios de cultivo celular.
WO2015095240A3 (en) Biosynthesis of 1-undecence and related terminal olefins
GB2514741A (en) Composition for use as a paint binder
MX2012014304A (es) Carboxamidas de pirazinilo como fungicidas.
WO2012157872A3 (ko) 고화 방지 감미 소재 조성물 및 그의 제조 방법
MX2021001790A (es) Composiciones solidas de trigliceridos y usos de estas.
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2012125552A3 (en) Methods of electric field induced delivery of compounds, compositions used in delivery, and system of delivery
EP3572506A3 (en) Glucoamylase variants
MX2016006790A (es) Producto cosmetico con propiedades reparadoras del adn.